SACHA Ancillary Studies

Retrospective, multicenter observational study on the use of Venetoclax in relapsed or refractory T-ALL in children and young adults aged 0 to 25 years

Status:
Data collection ongoing
Approval date: 02/10/2023

Real-world experience of larotrectinib in patients with TRK fusion solid tumors collected in the SACHA-France study

Status:
Ongoing
Approval date: 23/11/2020

Comprehensive postmarketing observational study to assess the experimental anticancer therapy for children and adolescents in France

Status:
Ongoing
Approval date: 06/12/2021

Real-world data on regorafenib ± cobimetinib in patients with relapsed osteosarcoma and Ewing sarcoma in the SACHA-France study

Status:
Published
View publication
More analysis ongoing
Approval date: 05/12/2022

Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high risk neuroblastoma: does chemotherapy backbone matter?

Status:
Published
View publication
More analysis ongoing
Approval date: 05/12/2022

Feasibility of a precision use program (ONC201) for patients with progression of H3K27-altered high grade glioma

Status:
Ongoing
Approval date: 05/12/2022

The value of central retrospective reviewing of radiological response within the SACHA-France experience

Status:
Published
View publication
Approval date: 26/04/2024

Safety of trametinib monotherapy or in combination with dabrafenib in patients with relapsed or refractory LGG and HGG

Status:
Ongoing
Approval date: 13/07/2024

Efficacy and safety of tovorafenib in SACHA

Status:
Ongoing
Approval date: 27/12/2024

Efficacy and Toxicity of MEK inhibitors in Children and adolescents with BRAF-V600E Mutant Glioma and HGG: real-world outcomes from the SACHA study

Status:
Ongoing
Approval date: 13/07/2023

Clinical and biological study of unmet medical need in childhood cancer

Status:
Ongoing
Approval date: 02/10/2023

Lorlatinib in patients relapsed/progressive high risk neuroblastoma

Status:
Published
View publication
More analysis ongoing
Approval date: 02/10/2023

Reason for prescription of off-label and compassionate use anticancer drugs in children, adolescents and young adults with solid tumors in France between 2020-2024, the SACHA-France experience

Status:
Ongoing
Approval date: 26/04/2024

Multicenter Retrospective Study of the Use of PD1/PD-L1 inhibitors in ITU or off-label in situation of Therapeutic Failure or Relapse

Status:
Ongoing
Approval date: 26/04/2024

Retrospective study of the efficacy and safety of Trametinib for the treatment of plexiform neurofibromas in patients with NF1

Status:
Ongoing
Approval date: 13/07/2024

PRO-SACHA: Patient Reported Outcome measurement questionnaire within the SACHA study to evaluate access to innovative medicines for Children and AYA (SACHA) study

Status:
Ongoing
Approval date: 23/09/2024